Biotech companies in San Diego: 454 labs and plants, and who spends the most on R&D

This report is for people deciding which San Diego biotechs to apply to, invest in, partner with or sell to. It counts the industry three ways (Census establishments, SEC-listed companies and federal research awards) and then shows how to shortlist. The Census metro is all of San Diego County, from Chula Vista to Carlsbad and Oceanside.

How many biotech companies are in San Diego

County Business Patterns (CBP) 2023, San Diego-Chula Vista-Carlsbad, CA Metro Area (CBSA 41740), NAICS 541714 and 325414 combined:

The two codes split very unevenly. Research and development in biotechnology (541714) has 437 establishments and 20,270 employees; biological product manufacturing (325414) has 17 establishments and 1,386 employees. San Diego is a research cluster first.

CBP counts establishments with paid employees, not companies: a biotech with two buildings counts twice, and founders with no payroll aren't counted at all.

Most labs are tiny

The combined size table is mostly withheld, because the Census Bureau doesn't publish most size classes for the 17 manufacturing sites. In the combined file, 232 establishments have 1 to 4 employees and 35 have 50 to 99; the other classes are not published. The R&D code on its own is published in full:

The Census file marks the 500 to 999 cell as not published; 2 is the total less the published classes. More than half the labs have fewer than five people, which matches a market of seed-stage startups, virtual biotechs run by a few executives, and incubator tenants.

What the two codes leave out

NAICS 541714 and 325414 capture biotech labs and biologics plants, but the Census Bureau's own cross-references send related work elsewhere:

• Drug discovery labs coded as other life-sciences R&D (541715), which is where many small-molecule companies land.
• Pharmaceutical preparation plants (325412) and diagnostic substance makers (325413).
• Testing labs and CROs coded 541380, and clinical labs coded 621511.
• Head offices, which are classed by function rather than industry, so a commercial biotech's corporate headquarters may not be in either code.

So treat 454 as the core of the industry, not all of it. Biocom California's 2026 Economic Impact Report, which uses a broad life-sciences definition, counts 61,866 direct life-science jobs in San Diego in 2025.

The biggest R&D budgets among listed companies

SEC EDGAR has 63 listed companies with a San Diego County business address in SIC 2836 (biological products, 17 companies) and 2834 (pharmaceutical preparations, 46); none are in 8731. Ranked by research and development expense in their latest 10-K, all for calendar 2025:

R&D and revenue as tagged in each 10-K's financial statements. The cash column is our sum of the balance-sheet lines for cash and cash equivalents and short-term investments.

Halozyme Therapeutics has the second-largest revenue in the county ($1,396.6 million) but spent $81.5 million on R&D, because most of its income is royalties. Ligand Pharmaceuticals still has a San Diego address in EDGAR, but its 10-K cover gives Jupiter, Florida, so it's left out.

The table is a hiring and spending map. Viking, Janux and Kura hold large cash balances with little revenue, so their spending is set by the board's trial plans rather than by sales. Companies with under two years of cash at their current R&D rate tend to cut programs first and buy less.

Where the research money comes from

NIH RePORTER shows $1.04 billion of NIH awards in fiscal 2025 (October 2024 to September 2025) to 111 organizations in San Diego County, across 1,550 projects. UC San Diego received $569.6 million, Scripps Research $164.4 million, the Salk Institute $61.0 million, Sanford Burnham Prebys $45.3 million and La Jolla Institute for Immunology $31.1 million. La Jolla addresses took 86% of the total.

For-profit companies received 117 awards worth $87.9 million, 106 of them small-business (SBIR or STTR) grants. The largest company recipients were Ensysce Biosciences ($5.3 million), Vivreon Biosciences ($4.1 million) and Novomedix ($3.3 million). RePORTER is a good way to find private startups that never appear in EDGAR.

FDA registrations: who makes biologics here

FDA's biologics registration has two parts. Blood and cell or tissue establishments register with FDA's biologics center; other biologics makers register as drug establishments. Companies that only make investigational products for trials don't have to register until approval, so most of the table above won't appear.

• Cell and tissue (HCT/P) registry: 8 registered San Diego County establishments list blood stem cell (HPC) or peripheral blood mononuclear cell products, including Rady Children's Hospital, San Diego Blood Bank, Scripps Green Hospital and Sanguine Biosciences.
• Drug establishment registry: registrants with manufacturing operations include Genentech and Gilead Sciences in Oceanside, and Tanvex BioPharma USA and Wacker Biotech US in San Diego.

How to check a San Diego biotech before you commit

1. Read the latest 10-K for listed companies: cash, R&D, headcount and the trial calendar are all there.
2. Search NIH RePORTER by organization name for grant history, including private companies.
3. Check FDA registration if the company says it manufactures: the cell and tissue query and the drug establishment file are both public.
4. Use the local directory. Biocom California publishes a member directory and runs the Career Hub job board.

Selling to San Diego biotechs

Worked example: a preclinical CRO

Illustrative example. The company and the outsourcing share are invented; the R&D figures come from the 10-Ks above.

Kelp Bay Preclinical (kelpbay.example) runs animal pharmacology studies for drug developers.

1. Pick accounts by budget, not revenue. Eight companies in the table spent over $100 million on R&D with under $100 million of revenue: $1,336.4 million in total.
2. Size the opportunity. If 2% of that goes to outside preclinical studies, the pool is about $26.7 million a year. A 5% share is $1.3 million.
3. Time the outreach. A new IND filing or a program moving into the clinic usually means new toxicology and pharmacology work; the 10-K's pipeline table shows which programs are next.

Building that list by hand means reading a dozen 10-Ks. Bebop researches each company on a list and suggests who to approach first.

For the companies that dominate national rankings, see the largest biotech companies, and for the manufacturing side of the region, the San Diego pharmaceutical market report.

Next step: compare the much larger Massachusetts cluster in biotech companies in Massachusetts.